PP
ENTA icon

PDT Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

PDT Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-69,197
Closed -$1.09M – 555
2025
Q4 		$1.09M Sell
69,197
-16,825
-20% -$214K 0.07% 342
2025
Q3 		$1.03M Sell
86,022
-730
-0.8% -$5.83K 0.06% 349
2025
Q2 		$656K Sell
86,752
-19,448
-18% -$117K 0.04% 487
2025
Q1 		$586K Buy
106,200
+72,751
+217% +$449K 0.04% 496
2024
Q4 		$192K Buy
33,449
+107
+0.3% +$1.03K 0.02% 660
2024
Q3 		$345K Sell
33,342
-2,901
-8% -$37.9K 0.03% 578
2024
Q2 		$470K Sell
36,243
-3,484
-9% -$47K 0.04% 477
2024
Q1 		$694K Sell
39,727
-23,498
-37% -$311K 0.07% 398
2023
Q4 		$595K Sell
63,225
-4,093
-6% -$38.1K 0.07% 375
2023
Q3 		$752K Buy
67,318
+39,699
+144% +$639K 0.09% 350
2023
Q2 		$591K Buy
+27,619
New +$814K 0.08% 354
2022
Q3 		– Sell
-11,597
Closed -$548K – 907
2022
Q2 		$548K Buy
+11,597
New +$629K 0.05% 572
2021
Q4 		– Sell
-12,954
Closed -$736K – 905
2021
Q3 		$736K Sell
12,954
-9,946
-43% -$492K 0.05% 401
2021
Q2 		$1.01M Buy
22,900
+3,137
+16% +$154K 0.07% 378
2021
Q1 		$975K Sell
19,763
-4,137
-17% -$206K 0.07% 376
2020
Q4 		$1.01M Buy
23,900
+4,500
+23% +$198K 0.07% 322
2020
Q3 		$888K Sell
19,400
-9,542
-33% -$462K 0.06% 327
2020
Q2 		$1.45M Buy
+28,942
New +$1.5M 0.1% 237
2015
Q4 		– Sell
-13,485
Closed -$487K – 561
2015
Q3 		$487K Buy
13,485
+7,243
+116% +$311K 0.01% 908
2015
Q2 		$281K Sell
6,242
-7,826
-56% -$304K 0.01% 1150
2015
Q1 		$431K Buy
+14,068
New +$547K 0.01% 1067
2014
Q4 		– Sell
-36,096
Closed -$1.43M – 764
2014
Q3 		$1.43M Buy
+36,096
New +$1.44M 0.04% 520

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PDT Partners's ENTA Position: Q1 2026 in Review

PDT Partners sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 69,197 shares — an estimated $1.09M sold.

PDT Partners first reported a position in ENTA in Q3 2014 and held it in 22 quarters. The position peaked at $1.45M in Q2 2020. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • PDT Partners reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • PDT Partners sold 69,197 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.09M.
  • PDT Partners first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 22 quarters.
  • PDT Partners's Enanta Pharmaceuticals position peaked at $1.45M in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.